⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29391325 | 1.00 | — | — | |
| Fluoride SCHEMBL27279145 | 0.97 | ALDH1A1 (0.42) | — | |
| Fluoride SCHEMBL27598987 | 0.97 | ALDH1A1 (0.42) | — | |
| Magnesium SCHEMBL31567264 | 0.97 | ALDH1A1 (0.42) | — | |
| SCHEMBL168931 | 0.79 | — | — | |
| Chlorocresol SCHEMBL875121 | 0.78 | ALOX15 (0.52) | — | |
| SCHEMBL3747323 | 0.77 | CYP3A4 (0.50) | — | |
| SCHEMBL40336 | 0.75 | — | — | |
| SCHEMBL125688 | 0.75 | — | — | |
| SCHEMBL29419590 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 502 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118652170-A | New synthesis method of 5-bromo-2-chlorobenzoic acid | 宁夏法安德药业有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-107652276-A | A kind of preparation method net SGLT2 inhibitor Yi Palie | 江苏工程职业技术学院 | 2018-02-02 | — | — | CN | claimed |
| CN-104478670-B | The preparation method of the bromo-2-of 5-chloro-4 '-ethoxy diphenyl methane | 中国药科大学 | 2016-08-17 | — | — | CN | claimed |
| JP-54151945-A | — | — | None | — | — | JP | disclosed |
| CN-116829545-B | Substituted pyrazolylpiperidine carboxylic acids | 拜耳公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2025228892-A1 | MONOARYL AND HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-06 | — | — | WO | disclosed |
| US-20250333398-A1 | MONOARYL AND HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2025-10-30 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| CN-120208766-A | Dapagliflozin intermediate bromine of (2) Process and apparatus for producing substitute | 浙江江北南海药业有限公司 | 2025-06-27 | — | — | CN | disclosed |
| US-5380848-A | 8-azabicyclo(3.2.1)octanes | RESEARCH TRIANGLE INSTITUTE (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0644775-A4 | COCAINE RECEPTOR BINDING LIGANDS. | RES TRIANGLE INST (US) | 1994-10-19 | — | — | EP | disclosed |
| WO-1993009814-A1 | COCAINE RECEPTOR BINDING LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 1993-05-27 | — | — | WO | disclosed |
| US-5138031-A | LINEAR AND BRANCHED POLY-P-ARYLENE SULFIDE SUBSTANTIALLY FREE FROM DEFECT STRUCTURES HAVING PLURAL ABSORPTION MAXIMA | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-11 | — | — | US | disclosed |
| EP-0077537-B1 | PROCESS FOR PREPARING 6-CHLORO-3-TOLUIDINO-4-SULPHONIC ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-10-02 | — | — | EP | disclosed |
| US-RE31412-E | FLUORAN COMPOUND AS COLOR-FORMER | YAMAMOTO KAGAKU GOSEI KABUSHIKI KAISHA (JP) | 1983-10-11 | — | — | US | disclosed |
| EP-0077537-A2 | Process for preparing 6-chloro-3-toluidino-4-sulphonic acid | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-04-27 | — | — | EP | disclosed |
| JP-S54151945-A | PREPARATION OF 6-CHLORO-3-TOLUIDINE-4-SULFONIC ACID | HODOGAYA CHEM CO LTD | 1979-11-29 | — | — | JP | disclosed |
| US-3947460-A | SEDATIVES-HYPNOTIC, TRANQUILIZER | SANDOZ, INC. (US) | 1976-03-30 | — | — | US | disclosed |